Free Newsletter
ALSO NOTED: Eisai inks $3.9B deal for MGI; Reckitt Benckiser buying Adams for $2.3B;
> Japan's Eisai Pharmaceuticals says it's buying biotech company MGI Pharma for $3.9 billion; you'll recall that MGI announced that it was looking for "strategic alternatives" a few weeks ago. Release
> The UK's Reckitt Benckiser says it's bidding $2.3 billion for U.S.-based Adams Respiratory Therapeutics, a maker of over-the-counter cough and cold remedies. Report
> Abbott Laboratories has sued two generics firms seeking approval to sell generic versions of the epilepsy drug Depakote ER. Sandoz and Cadila Healthcare say their copycat drugs won't infringe on the patents for controlled-release Depakote, which expire in 2018. Report
> Biovail has added Thallion Pharmaceuticals CEO Lloyd M. Segal to its board of directors. Report
> GE Healthcare and Novavax are collaborating on a quick-to-launch manufacturing system for avian flu vaccine. Report
And Finally... People taking antidepressants were more likely to develop Parkinson's Disease, suggesting that depression may be an early symptom of the disorder. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: